Ro 41-5253

Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity[1][2].

Product Specifications

CAS Number

[144092-31-9]

UNSPSC

12352005

Target

Apoptosis; RAR/RXR

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ro-41-5253.html

Purity

98.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(C=C1)/C=C(C)/C2=C(C=C3C(C(C)(CCS3(=O)=O)C)=C2)OCCCCCCC)O

Molecular Formula

C28H36O5S

Molecular Weight

484.65

References & Citations

[1]S Toma, et al. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer. 1998 Sep 25;78 (1) :86-94|[2]Salvatore Toma, et al. Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha. Cancer Lett. 2005 Feb 28;219 (1) :27-31. doi: 10.1016/j.canlet.2004.06.018.|[3]C Apfel, et al. A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A. 1992 Aug 1;89 (15) :7129-33.